BioSpace News Archive

2seventy bio, Inc. today announced its official launch as an independent, publicly traded company. 2seventy bio will trade on the Nasdaq Global Select Market, commencing tomorrow, November 5 under the ticker symbol “TSVT.”

Surface Oncology today reported financial results for the third quarter 2021, and provided a corporate update on recent highlights and anticipated near-term milestones.

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted authorization in the United Kingdom for molnupiravir, the first oral antiviral medicine authorized for the treatment of mild-to-moderate COVID-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk factor for developing severe illness.

AdaptHealth Corp., a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced financial results for the third quarter ended September 30, 2021.

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced it received market authorization from the Australian Therapeutic Goods Administration for the sale of PoNS as a Class IIa medical device.

Jounce Therapeutics, Inc., a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Passage Bio, Inc., a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, reported financial results for the third quarter ended September 30, 2021 and provided recent business highlights.

Antares Pharma, Inc., a specialty pharmaceutical company, reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share.

Baudax Bio, Inc., a pharmaceutical company focused on commercializing and developing innovative products for acute care settings, reported financial results for the three and nine months ended September 30, 2021, and provided key metrics around the ongoing commercial rollout of ANJESO® injection and updated status of neuromuscular blocking agent BX1000 dose escalation study.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, provided a corporate and financial update for the third quarter ended September 30, 2021.